| Identification | Back Directory | [Name]
Nemolizumab | [CAS]
1476039-58-3 | [Synonyms]
Nemolizumab
Research Grade Nemolizumab
Research Grade Nemolizumab(DHJ26601) |
| Hazard Information | Back Directory | [Uses]
Nemolizumab (CIM331) is a humanized monoclonal antibody that targets the human interleukin-31 receptor a, preventing interleukin-31 (IL-31) from binding to its receptor and the subsequent signaling. Nemolizumab can help reduce itching and sleep disturbances, and it is being studied for atopic dermatitis (AD)[1][2]. | [in vivo]
Nemolizumab (40-100 μg/kg, i.v., acute administration) blocks IL-31-induced scratching in cynomolgus monkeys[3].
Nemolizumab (1 mg/kg, s.c., acute administration) exerts a mean plasma concentration of 1490 ng/mL at Day 56 in 5 of 6 experiment cynomolgus monkeys and suppresses the scratching behaviour from shortly after administration until Day 56[3].
| [References]
[1] Nakahara T, et, al. Nemolizumab and Atopic Dermatitis: the Interaction Between Interleukin-31 and Interleukin-31 Receptor as a Potential Therapeutic Target for Pruritus in Patients With Atopic Dermatitis. 2018;5:405–14.
[2] O Nemoto, et al. The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled study. Br J Dermatol. 2016 Feb;174(2):296-304. DOI:10.1111/bjd.14207
[3] Oyama S, et al. Cynomolgus monkey model of interleukin-31-induced scratching depicts blockade of human interleukin-31 receptor A by a humanized monoclonal antibody. Exp Dermatol. 2018 Jan;27(1):14-21. DOI:10.1111/exd.13236 |
|
| Company Name: |
Biolab Reagents Gold
|
| Tel: |
18108604356 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|